Literature DB >> 2515796

Comparative in vitro activities of pristinamycin and other antimicrobial agents against genital pathogens.

J C Lefevre1, R Bauriaud.   

Abstract

The MICs of pristinamycin for genital pathogens were compared with those of ampicillin, tetracycline, erythromycin, and ciprofloxacin. Pristinamycin was active against all the strains studied. Because of this activity and its lack of toxicity, pristinamycin might be a valuable therapeutic agent for treating major sexually transmitted diseases.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2515796      PMCID： PMC172841          DOI： 10.1128/AAC.33.12.2152

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Antibiotics of the virginiamycin family, inhibitors which contain synergistic components.

Authors:  C Cocito
Journal:  Microbiol Rev       Date:  1979-06

2.  Antibiotic susceptibility of 83 penicillinase-producing Neisseria gonorrhoeae strains isolated in France (May 1979-April 1983).

Authors:  J Y Riou; I Lind; M Guibourdenche
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

3.  Comparative evaluation of macrolides, lincosamides and streptogramins in staphylococcal infections.

Authors:  J Modai
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

4.  Comparative in vitro activities of pristinamycin, its components, and other antimicrobial agents against anaerobic bacteria.

Authors:  H Laforest; M Fourgeaud; H Richet; P H Lagrange
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

5.  [Surveillance of Neisseria gonorrhoeae strains isolated in Toulouse. In vitro antibiotic sensitivity and plasmid content].

Authors:  J C Lefevre; E Gaubert; M C Tempesta; M B Lareng
Journal:  Pathol Biol (Paris)       Date:  1988-06

6.  Lower genital tract infections in women: comparison of clinical and epidemiologic findings with microbiology.

Authors:  J C Lefèvre; S Averous; R Bauriaud; C Blanc; M A Bertrand; M B Lareng
Journal:  Sex Transm Dis       Date:  1988 Apr-Jun       Impact factor: 2.830

7.  Antimicrobial activity of U-70138F (paldimycin), roxithromycin (RU 965), and ofloxacin (ORF 18489) against Chlamydia trachomatis in cell culture.

Authors:  W E Stamm; R Suchland
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

8.  In-vitro comparison of macrolides, lincosamides and synergistins on Neisseria gonorrhoeae.

Authors:  A Thabaut; M Meyran; M Huerre
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

9.  Structure activity relationships in lincosamide and streptogramin antibiotics.

Authors:  F Le Goffic
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790
  9 in total
  5 in total

1.  Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.

Authors:  A B Reid; J R Daffy; P Stanley; K L Buising
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Growth and development of tetracycline-resistant Chlamydia suis.

Authors:  J Lenart; A A Andersen; D D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145.

Authors:  R Rende-Fournier; R Leclercq; M Galimand; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2.

Authors:  Rachel Binet; Anthony T Maurelli
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.